Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study

Stein, Dan J., Ahokas, Antti A., de Bodinat, Christian·2008·Journal of Clinical Psychopharmacology

Abstract

BACKGROUND: Agomelatine is a novel agent that acts on melatonergic (MT(1), MT(2)) receptors and serotonergic (5-HT(2C)) receptors. Preclinical data and data from clinical trials in major depression suggest that agomelatine may have anxiolytic properties. A randomized, double-blind, placebo-controlled trial was designed to assess the efficacy of agomelatine in generalized anxiety disorder (GAD). METHODS: One hundred twenty-one patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition GAD and no comorbid disorders were randomized to agomelatine (25-50 mg/d) or placebo for 12 weeks. The primary outcome measure was the Hamilton Anxiety Rating Scale, whereas secondary outcome measures included the Clinical Global Impression scales, the Leeds Sleep Evaluation Questionnaire, and the Sheehan Disability Scale. Safety measures included assessment of spontaneously reported adverse events, laboratory monitoring, and the Discontinuation Emergent Signs and Symptoms Scale to evaluate discontinuation symptoms. RESULTS: Analysis of covariance of change in the last Hamilton Anxiety Rating Scale total score from baseline demonstrated significant superiority of agomelatine 25 to 50 mg as compared with placebo (E [SE] = -3.28 [1.58]; 95% confidence interval = -6.41 to -0.15; P = 0.040). Data on secondary outcome measures, including clinical response, symptoms of insomnia, and improvement in associated disability, were consistent with the efficacy of agomelatine. Safety analysis indicated that agomelatine was tolerated as well as placebo and was devoid of discontinuation emergent symptoms. CONCLUSIONS: This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated. Additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomelatine in the contemporary pharmacotherapy for anxiety disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318184ff5b

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 22

  1. Millan, 2003, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways., J Pharmacol Exp Ther, 306, 954, 10.1124/jpet.103.051797 · DOI · Paper page
  2. Millan, 2005, Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade., Psychopharmacologia, 177, 448, 10.1007/s00213-004-1962-z · DOI · Paper page
  3. Loiseau, 2006, Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam., Eur Neuropsychopharmacol, 16, 417, 10.1016/j.euroneuro.2005.11.007 · DOI
  4. Papp, 2006, Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety., Behav Pharmacol, 17, 9
  5. Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study., Int Clin Psychopharmacol, 17, 239, 10.1097/00004850-200209000-00004 · DOI · Paper page
  6. Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European neuropsychopharmacology., Eur Neuropsychopharmacol, 16, 93, 10.1016/j.euroneuro.2005.09.002 · DOI · Paper page
  7. Olie, 2007, Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder., Int J Neuropsychopharmacol, 4, 1
  8. Den Boer, 2006, Clinical efficacy of agomelatine in depression: the evidence., Int Clin Psychopharmacol, 21, S21, 10.1097/01.yic.0000195661.37267.86 · DOI
  9. Dubocovich, 2006, Agomelatine targets a range of major depressive disorder symptoms., Curr Opin Investig Drugs, 7, 670
  10. Ballenger, 2001, Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety., J Clin Psychiatry, 62, 53
  11. Bandelow, 2002, WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and posttraumatic stress disorders. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders., World J Biol Psychiatry, 3, 171, 10.3109/15622970209150621 · DOI · Paper page
  12. Allgulander, 2003, WCA recommendations for the long-term treatment of generalized anxiety disorder., CNS Spectr, 8, 53, 10.1017/S1092852900006945 · DOI
  13. Baldwin, 2005, Evidence-based pharmacotherapy of Generalized Anxiety Disorder., Int Clin Psychopharmacol, 8, 293
  14. Montgomery, 2004, Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study., Int Clin Psychopharmacol, 19, 271, 10.1097/01.yic.0000137184.64610.c8 · DOI · Paper page
  15. Kessler, 2000, The epidemiology of pure and comorbid generalized anxiety disorder. A review and evaluation of recent research., Acta Psychiatr Scand, 406, 7, 10.1111/j.0065-1591.2000.acp29-02.x · DOI
  16. Stein, 2001, Comorbidity in generalized anxiety disorder: impact and implications., J Clin Psychiatry, 62, 29
  17. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10., J Clin Psychiatry, 59, 22
  18. Hamilton, 1959, A rating scale for anxiety., J Neurol Neurosurg Psychiatr, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  19. Zigmond, 1983, The Hospital Anxiety and Depression Scale., Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
  20. Stein, 2005, Generalized anxiety disorder: rethinking diagnosis and rating., CNS Spectr, 10, 930, 10.1017/S1092852900010488 · DOI
  21. Parrott, 1980, The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review., Psychopharmacologia, 71, 173, 10.1007/BF00434408 · DOI · Paper page
  22. Rosenbaum, 1998, Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial., Biological Psychiatry, 44, 77, 10.1016/S0006-3223(98)00126-7 · DOI · Paper page

Cited by

See all 174

Metadata

Authors
Stein, D. J., Ahokas, A. A., & de Bodinat, C.
Venue
Journal of Clinical Psychopharmacology
Published
2008-10
Volume
28
Issue
5
Pages
561-566
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1967246300
Cited by
174
References
2
FWCI
20.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e318184ff5b
The paper
Stein, D. J., Ahokas, A. A., & de Bodinat, C. (2008). Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318184ff5b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.